Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

<p>A-C. FFPE sections of PC were stained by multiplex staining panel for CD4, CD8, FoxP3 (T regulatory cells), CD19 (B cells), CD68 (macrophages). Stained sections were imaged on the Hamamatsu slide scanner NanoZoomer S360 and images were viewed on the NDP viewer software. Analysis of images w...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Ulka N. Vaishampayan (15051039) (author)
مؤلفون آخرون:	Archana Thakur (15051042) (author), Wei Chen (15051045) (author), Abhinav Deol (15051048) (author), Meera Patel (15051051) (author), Kimberlee Dobson (15051054) (author), Brenda Dickow (15051057) (author), Dana Schalk (15051060) (author), Amy Schienschang (15051063) (author), Sarah Whitaker (15051066) (author), Amanda Polend (15051069) (author), Joseph A. Fontana (411960) (author), Elisabeth I. Heath (15024674) (author), Lawrence G. Lum (15051072) (author)
منشور في:	2025
الموضوعات:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

مواد مشابهة